{"id":"NCT03901352","sponsor":"Daiichi Sankyo Co., Ltd.","briefTitle":"Study of Mirogabalin for Central Neuropathic Pain","officialTitle":"An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-12","primaryCompletion":"2020-12-28","completion":"2020-12-28","firstPosted":"2019-04-03","resultsPosted":"2024-09-23","lastUpdate":"2024-10-21"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Central Neuropathic Pain"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":["Matching Placebo"]},{"type":"DRUG","name":"Mirogabalin","otherNames":["DS-5565"]}],"arms":[{"label":"Mirogabalin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Investigate the efficacy and safety of mirogabalin in participants with central neuropathic pain in comparison to placebo","primaryOutcome":{"measure":"Change From Baseline in the Weekly Average Daily Pain Score (ADPS) at Week 14 Following Administration With Mirogabalin or Placebo","timeFrame":"Baseline to Week 14 postdose","effectByArm":[{"arm":"Mirogabalin","deltaMin":-1.23,"sd":0.132},{"arm":"Placebo","deltaMin":-0.52,"sd":0.132}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":118,"countries":["Japan","South Korea","Taiwan"]},"refs":{"pmids":["38963656","37115464","36517235"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":151},"commonTop":["Somnolence","Nasopharyngitis","Oedema peripheral","Dizziness","Oedema"]}}